CDDO-TFEA

• Description:

  CDDO-TFEA (RTA 404; TP-500) is a trifluoroacetamide derivative of CDDO with enhanced ability to cross the blood-brain barrier. CDDO is an Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. CDDO-TFEA can enhance Nrf2 expression and signaling in various neurodegenerative disease models, including those mimicking multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. CDDO-TFEA induces apoptosis and blocks colony formation in Ewing's sarcoma and neuroblastoma cell lines with IC50 values ranging from 85-170 nM.

• Product Name Alternative:

  CDDO-Trifluoethyl amide; RTA 404; TP-500

• UNSPSC:

  12352211

• Target:

  Apoptosis; Keap1-Nrf2

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cddo-tfea.html

• Purity:

  99.59

• Solubility:

  DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H])[H])C)C(NCC(F)(F)F)=O)C)4C)5[H])C(C(C#N)=C[C@]5(C)C4=CC3=O)=O

• Molecular Formula:

  C33H43F3N2O3

• Molecular Weight:

  572.70

• References & Citations:

  [1]Stack, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic. Biol. Med. 49 (2), 147-158 (2010) .

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  932730-52-4